<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02489461</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-VM1500-04</org_study_id>
    <nct_id>NCT02489461</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretroviral Therapy</brief_title>
  <official_title>International, Multicenter, Randomized, Partially Blind Study to Evaluate Efficacy, Safety and Selection of the Optimal Dose for VM-1500 in Comparison to Efavirenz in Combination With Two NRTIs in Treatment-naïve, HIV-1 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viriom</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viriom</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is conducted in two stages and open-label stage of the study.

      At the first stage of the study, the main purpose was to choose the optimal dose of VM-1500
      (20 mg or 40 mg per day) in addition to standard-of-care basic antiretroviral therapy
      consisting of two NRTIs, in terms of reduction of viral load at Week 12 (&lt;400 copies/ml) in
      treatment-naïve HIV-1-infected patients.

      At the second stage of the study, the main purpose was to evaluate efficacy of VM- 1500 (in
      the optimal dose selected at the first stage of the study) in comparison to Efavirenz added
      to standard-of-care antiretroviral therapy of two NRTIs, in terms of reduction of viral load
      at Week 24 to the undetectable level (&lt;50 copies/ml) in treatment-naïve HIV-1 infected
      patients.

      Open-label stage of the study continued evaluation of viral load and immunological and safety
      parameters in HIV-1 patients receiving VM-1500 up to Week 96 and additional PK up to Week
      100.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is an international, multicenter, randomized, partially blind clinical study to
      evaluate efficacy and safety of two different doses of VM-1500 in comparison with Efavirenz
      added to standard antiretroviral therapy including two NRTIs in treatment-naïve
      HIV-1-infected patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 5, 2014</start_date>
  <completion_date type="Actual">September 18, 2017</completion_date>
  <primary_completion_date type="Actual">April 5, 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of HIV-1 RNA level in blood plasma &lt;400 copies/ml</measure>
    <time_frame>12 weeks</time_frame>
    <description>Comparison of the percentage of patients with reduced viral load to &lt; 400 copies/ml at Week 12 in VM-1500 20 mg, VM-1500 40 mg and Efavirenz treatment groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of HIV-1 RNA level in blood plasma &lt;50 copies/ml</measure>
    <time_frame>24 weeks</time_frame>
    <description>Comparison of the percentage of patients with reduced viral load to an undetectable level (&lt; 50 copies/ml) at Week 24 in VM-1500 group with the selected dose and Efavirenz group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of HIV-1 RNA level in blood plasma &lt;50 copies/ml</measure>
    <time_frame>48 weeks</time_frame>
    <description>Comparison of the percentage of patients with reduced viral load to an undetectable level (&lt; 50 copies/ml) at Week 48 in VM-1500 group with the selected dose and Efavirenz group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the absolute CD4+ lymphocytes count</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in the absolute CD4+ lymphocytes count from Baseline to Week 48 in VM-1500 group with the selected dose and Efavirenz group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the absolute CD8+ lymphocytes count</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in the absolute CD8+ lymphocytes count from Baseline to Week 48 in VM-1500 group with the selected dose and Efavirenz group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent of patients with study therapy-resistant HIV-1 development</measure>
    <time_frame>48 weeks</time_frame>
    <description>The proportion of patients who develop study therapy-resistant HIV-1 from Baseline to Week 48 in VM-1500 group with the selected dose and Efavirenz group.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>VM-1500 20 mg + ART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500 - 20 mg (Stage I), then optimal dose (Stage II and Open-Label Stage), ART</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VM-1500 40 mg + ART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500 - 40 mg (Stage I), then optimal dose (Stage II and Open-Label Stage), ART</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efavirenz 600 mg + ART</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Efavirenz 600 mg (Stage I and Stage II), ART</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VM-1500</intervention_name>
    <description>VM-1500 up to 96 weeks</description>
    <arm_group_label>VM-1500 20 mg + ART</arm_group_label>
    <arm_group_label>VM-1500 40 mg + ART</arm_group_label>
    <other_name>Elsulfavirine</other_name>
    <other_name>Elpida®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>Efavirenz up to 48 weeks</description>
    <arm_group_label>Efavirenz 600 mg + ART</arm_group_label>
    <other_name>Stocrin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiretroviral therapy (ART)</intervention_name>
    <description>Antiretroviral therapy up to 96 weeks</description>
    <arm_group_label>Efavirenz 600 mg + ART</arm_group_label>
    <arm_group_label>VM-1500 20 mg + ART</arm_group_label>
    <arm_group_label>VM-1500 40 mg + ART</arm_group_label>
    <other_name>standard antiretroviral therapy of two NNRTIs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Patient Information and Informed Consent Form.

          2. Males and females, age ≥ 18 years.

          3. HIV-1 infection, confirmed serologically in IFA or immunoblot analysis (or documented
             HIV-1 infection).

          4. Clinically stable HIV infection (clinical stages 1 or 2 according to the WHO
             classification).

          5. Indications (in the Investigator's opinion) for ART, according to the WHO Summary
             Guideline for use of antiretroviral drugs in HIV prevention and treatment (2013).

          6. HIV-1 RNA plasma level ≥ 5 000 copies/ml at screening.

          7. СD4+ Т-cells number &gt; 200 cells/mm3 at screening.

          8. Laboratory parameters as follows:

        White blood cells ≥ 2900/mm3 (2,9 x 109 cells/l) Absolute neutrophils ≥ 1500/mm3 (1,5 x 109
        cells/l) Platelets ≥ 100000/mm3 (100 x 109 cells/l) Hemoglobin ≥ 9.0 g/dl Total bilirubin ≤
        1.5 x ULN AST and ALT≤ 2.5 x ULN Renal function GFR &gt; 60 ml/min

        Exclusion Criteria:

          1. Primary HIV-1 resistance to ART. Viral resistance mutations are defined as any basic
             mutations of resistance to NNRTIs, according to the updated list of VIH-1 resistance
             mutations (International AIDS society, 2013), associated with drug resistance in any
             genotype.

          2. History of antiretroviral therapy (ART), including for the prevention of vertical
             transmission of HIV.

          3. Acute hepatitis or hepatic cirrhosis of any etiology; anti-HCV antibodies or HBsAg at
             screening.

          4. Signs of acute infection or positive test result for syphilis, hepatitis A, Toxoplasma
             gondii, cytomegalovirus, gonorrhea, Chlamydia trachomatis during 30 days before
             screening.

          5. Opportunistic infections of the Category C (Centers of Disease Control (CDC), 2008),
             excluding Kaposi's sarcoma not requiring systemic therapy.

          6. History of tuberculosis of any localization, or tuberculosis at screening, according
             to x-ray examination.

          7. History of malignant tumors (except basal cell carcinoma, squamous cell carcinoma, or
             cervical carcinoma in situ, eliminated and cured ≥ 5 years ago).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irina Y Tyrnova</last_name>
    <role>Study Chair</role>
    <affiliation>Viriom,LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaluga regional center for AIDS prevention</name>
      <address>
        <city>Kaluga</city>
        <state>Kaluga Region</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lipetsk regional center for AIDS prevention</name>
      <address>
        <city>Lipetsk</city>
        <state>Lipetsk Region</state>
        <zip>398043</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perm Regional center for AIDS prevention</name>
      <address>
        <city>Perm</city>
        <state>Perm Region</state>
        <zip>614088</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryazan Regional Clinical Dermatovenerologic Dispensary</name>
      <address>
        <city>Ryazan</city>
        <state>Ryazan Region</state>
        <zip>390046</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City center for AIDS prevention</name>
      <address>
        <city>Tolyatti</city>
        <state>Samara Region</state>
        <zip>445846</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican hospital for AIDS prevention</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan Republic</state>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Udmurtia Republican hospital for AIDS prevention</name>
      <address>
        <city>Izhevsk</city>
        <state>Udmurtia Republic</state>
        <zip>426067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volgograd regional center for AIDS prevention</name>
      <address>
        <city>Volgograd</city>
        <state>Volgograd Region</state>
        <zip>400040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Scientific Research Institute of Epidemiology</name>
      <address>
        <city>Moscow</city>
        <zip>105275</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Infectional Clinical Hospital #2</name>
      <address>
        <city>Moscow</city>
        <zip>105275</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Prevention AIDS Center</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Petersburg city center for AIDS prevention</name>
      <address>
        <city>St.Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical infectious diseases hospital n.a. S.P. Botkin&quot;</name>
      <address>
        <city>St.Petersburg</city>
        <zip>191167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>June 18, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2015</study_first_posted>
  <last_update_submitted>September 21, 2018</last_update_submitted>
  <last_update_submitted_qc>September 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

